KPF
ALXN

K2 Principal Fund’s Alexion Pharmaceuticals ALXN Stock Holding History

K2 Principal Fund’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,777
Closed -$6.39M – 532
2021
Q2 		$6.39M Buy
34,777
+4,777
+16% +$820K 0.53% 60
2021
Q1 		$4.59M Buy
30,000
+24,000
+400% +$3.71M 0.36% 70
2020
Q4 		$937K Buy
+6,000
New +$771K 0.08% 208

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

K2 Principal Fund's ALXN Position: Q3 2021 in Review

K2 Principal Fund sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 34,777 shares — an estimated $6.39M sold.

K2 Principal Fund first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $6.39M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • K2 Principal Fund reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • K2 Principal Fund sold 34,777 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.39M.
  • K2 Principal Fund first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • K2 Principal Fund's Alexion Pharmaceuticals position peaked at $6.39M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on K2 Principal Fund's 13F filing for Q3 2021, filed 12 Nov 2021.